103694-26-4 Usage
General Description
C-(2-Methyl-thiazol-4-yl)-Methylamine is a chemical compound falling under the category of Thiazoles, which are heterocyclic compounds with both sulfur and nitrogen. It is characteristically a derivative of methylamine and plays an integral part in various scientific research and studies. Being a compound of methylamine, it retains some properties of the parent molecule, including its basicity driven by the amine group. However, safety and handling aspects, such as toxicity levels, reactivity with other substances, and exposure potential remain largely undisclosed, emphasizing the need for caution and robust protective measures while working with this compound.
Check Digit Verification of cas no
The CAS Registry Mumber 103694-26-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,6,9 and 4 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 103694-26:
(8*1)+(7*0)+(6*3)+(5*6)+(4*9)+(3*4)+(2*2)+(1*6)=114
114 % 10 = 4
So 103694-26-4 is a valid CAS Registry Number.
InChI:InChI=1/C5H8N2S/c1-4-7-5(2-6)3-8-4/h3H,2,6H2,1H3
103694-26-4Relevant articles and documents
MACROCYCLES AS PDE1 INHIBITORS
-
, (2019/06/30)
The present invention provides macrocycles of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES
-
, (2019/07/19)
The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.
1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS
-
, (2018/09/25)
The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
